ChartMill · Mar 20, 2026
Top movers in Friday's session
Keep an eye on the top gainers and losers in Friday's session, as they reflect the most notable price movements.
NASDAQ · SLXNW
Silexion Therapeutics Ltd.
Healthcare · Biotechnology
$0.01
Down-$0.00 (-2.21%)
Updated Sep 19, 2026, 4:41 PM
SID Score
2.8/10
Composite research score
Smart Money
—
Institutional and insider signal
- Market cap
- 16.83K
- P/E ratio
- -0.1
- Dividend yield
- 0.00%
- 52-week range
- $0.01 – $0.15
- Volume
- 10.09K
- Avg. volume
- 60.31K
Price performance
SLXNW price history
1M range · 13 trading sessions · Daily adjusted prices
SLXNW closed at $0.01 after 13 trading sessions, down 5.64% for the selected period.
- Last close
- $0.01
- Period change
- -5.64%
- Period low
- $0.01
- Period high
- $0.01
Daily close
View OHLC price history
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Sep 18, 2026 | $0.011 | $0.011 | $0.0106 | $0.0108 | 10.09K |
| Sep 17, 2026 | $0.0108 | $0.011 | $0.0108 | $0.011 | 15.16K |
| Sep 16, 2026 | $0.0113 | $0.0113 | $0.0108 | $0.011 | 992 |
| Sep 15, 2026 | $0.012 | $0.012 | $0.012 | $0.012 | 7.31K |
| Sep 14, 2026 | $0.012 | $0.012 | $0.0113 | $0.0113 | 3.07K |
| Sep 10, 2026 | $0.012 | $0.012 | $0.0117 | $0.0117 | 4.86K |
| Sep 8, 2026 | $0.0139 | $0.0139 | $0.0113 | $0.012 | 18.98K |
| Sep 2, 2026 | $0.014 | $0.014 | $0.014 | $0.014 | 3.1K |
| Sep 1, 2026 | $0.0113 | $0.014 | $0.0113 | $0.0113 | 1.09K |
| Aug 31, 2026 | $0.014 | $0.014 | $0.0126 | $0.014 | 3.98K |
| Aug 28, 2026 | $0.0124 | $0.014 | $0.0124 | $0.014 | 5.46K |
| Aug 27, 2026 | $0.0127 | $0.014 | $0.0127 | $0.014 | 4.26K |
| Aug 26, 2026 | $0.014 | $0.014 | $0.0114 | $0.0114 | 13.27K |
Latest SLXNW news
The latest Smart Investors Daily articles mentioning SLXNW.
Stock researchCompany · Overview
SLXNW research
Overview
Company profile and research snapshot.
Company profile
Silexion Therapeutics Corp a clinical-stage, oncology-focused biotechnology company engaged in the discovery and development of proprietary treatments for KRAS-driven cancers. The KRAS gene is an oncogene that is involved in the regulation of cell division as a result of its ability to relay external signals into the cell. Its product candidate, SIL204, consists of locally administered small interfering RNAs, or siRNA, in a solution, as a first-line treatment of locally advanced pancreatic cancer patients, or LAPC, in combination with standard-of-care chemotherapy. It is currently focused on treatment for pancreatic cancer tumors bearing the KRAS G12D or KRAS G12V mutations where metastases have not been detected and are non-resectable, i.e. it is not able to be surgically removed.
Visit company websiteAnalyst outlook
Consensus and target data currently published for this company.
- Consensus
- —
- Average target
- —
- Implied upside
- —
- Analysts
- —
News briefing
No generated briefing is available yet.
ChartMill · Mar 16, 2026
These stocks are moving in today's session
Intrigued by the market activity one hour before the close of the markets on Monday? Uncover the key winners and losers of today's session in our insightful analysis.
ChartMill · Mar 16, 2026
Wondering what's happening in today's pre-market session?
Wondering what's happening in Monday's pre-market session? Find an overview in this article.
Yahoo · Nov 12, 2025
Silexion Therapeutics Reports Third Quarter 2025 Financial Results and Provides Business Update
Continued advancement toward Phase 2/3 clinical trial initiation, on track for the first half of 2026 New preclinical data demonstrated SIL204’s exceptional efficacy across multiple human cancer cell lines, highlighting potential effectiveness against five KRAS-driven cancer types Successfully raised over $9 million during the third quarter, significantly strengthening the Company’s balance sheet Grand Cayman, Cayman Islands, Nov. 12, 2025 (GLOBE NEWSWIRE) -- Silexion Therapeutics Corp. (NASDAQ:
AI research layers
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
